Miami Cancer Institute Breast Cancer Genetics Update
Miami Cancer Institute’s Breast Cancer Genetics Update provides a comprehensive overview of breast cancer treatment and genomic testing in patients with BRCA1/2 +/- PALB2, HR+/HER2- breast cancer, HER2+ disease, triple-negative breast cancer and populations with ESR1 mutations.
Deaths per year from breast cancer are declining because of advances in HER2+ disease. The incorporation of genomic assays has allowed us to better tailor our treatment recommendations for patients with HR+/HER2- breast cancer. A better understanding of molecular mechanisms underlying pathogenesis of HER2+ disease has generated targeted therapy options to combat this poor prognosis. This course provides learners with an overview of the recent advances in available treatment for HR+/HER2- early breast cancer patients and in advanced disease populations with ESR1 mutation.
This course also addresses current and emerging therapeutic options for triple-negative breast cancer. The role of adjuvant immunotherapy in early-stage disease is discussed, as well as the role of additional therapy in those patients with residual disease. The course assesses the chemotherapy backbone of treatment planning in triple-negative patients.
This course concludes by delving further into genetic testing. The role of a cancer genetic counselor becomes essential when considering universal testing for the most actionable genes (BRCA1/2 +/- PALB2) and guiding treatment plans when multi-gene panels identify genes of uncertain significance.
- Breast Cancer Genomic Testing – Clinical Applications
- Challenges in HER2+ Breast Cancer
- Current and Emerging Therapeutic Options for Triple-Negative Breast Cancer: Immunotherapy and Beyond
- Universal Testing for Breast Cancer Predisposition
Breast Surgeons, General Surgeons, Reconstructive Surgeons, Obstetricians and Gynecologists, Oncologists, Medical Oncologists, Physiatrists, Radiation Oncologists, Psychiatrists, Pathologists, Geneticists, Radiologists, General Practitioners, Nurses, Advanced Practice Registered Nurses, Physician Assistants/Physician Associates, Patient Navigators, Psychiatrists and all other interested healthcare professionals.
- Incorporate genomic assays to better tailor treatment recommendations for patients with HR+/HER2- breast cancer.
- Examine the benefits of chemotherapy over ovarian function suppression in premenopausal women.
- Utilize adjuvant therapies for high-risk patients with HR+/HER2- early breast cancer.
- Discuss how ESR1 mutation testing is now actionable in advanced disease populations.
- Define advanced triple-negative breast cancer (TNBC) standard of care treatment vs. early TNBC standard of care and explain investigational agents/regimens.
- Recognize molecular mechanisms underlying pathogenesis of HER2+ disease and develop targeted therapy to combat poor prognosis.
- Explain genetic testing criteria and examine the performance characteristics of testing criteria (sensitivity, specificity, PPV, NPV).
- Recognize the implications of including moderate penetrance genes in broad genetic testing.
Baptist Health gratefully acknowledges the commercial support provided by AstraZeneca.
Anne P. O'Dea, M.D.
Breast Cancer Clinical Research Program Services
The University of Kansas Medical Center
Kansas City, Kansas
Reshma Mahtani, D.O.
Chief of Breast Medical Oncology
Miami Cancer Institute
Rita Nanda, M.D.
Director of Breast Oncology Program
Department of Medicine, The University of Chicago
Mark Robson, M.D.
Chief of Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, New York
Anne O'Dea, M.D., faculty for this educational activity, is a speaker and consultant for Puma Biotechnology, Pfizer Pharmaceutical, AstraZeneca, Daiichi-Sankyo, Gilead Sciences, Seagen Biotechnology and Novartis Pharmaceuticals, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Reshma Mahtani, D.O., co-director and faculty for this educational activity, is a consultant/adviser for Agendia, Amgen, AstraZeneca, Daiichi-Sankyo, Eisai Pharmaceutical, Gilead Sciences, Hologic, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, Seagen and Puma Biotechnology. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Rita Nanda, M.D., faculty for this educational activity, is a researcher for Arvinas Pharmaceutical, Celgene Pharmaceutical, Corcept Therapeutics Pharmaceutical, AstraZeneca, Gilead Sciences, Merck & Co. Pharmaceutical, Seagen Biotechnology, Genentech Biotechnology, ImmunoGen, Roche Holding AG Pharmaceutical, OBI Pharma, OncoSec Medical, Pfizer, Relay Therapeutics, Sun Pharmaceutical Industries, Taiho Pharmaceutical, BeyondSpring Biotech, Fujifilm Pharmaceuticals U.S.A., GE HealthCare, Sanofi Pharmaceutical, Infinity Pharmaceuticals and iTeos Therapeutics. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Mark Robson, M.D., faculty for this educational activity, is a researcher for AstraZeneca, Merck and Pfizer, and an adviser for Artios Pharma Limited, Daiichi-Sankyo, Epic Sciences, Tempus Labs and Zenith Pharma. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
John Diaz, M.D., co-director of this educational activity, is a researcher for Merck & Co. and AstraZeneca.
All of the relevant financial relationships listed for these individuals have been mitigated.
Starr Mautner, M.D., co-director of this educational activity, has no relevant financial relationships with ineligible companies* to disclose.
Eric Schroeder, M.D., co-director of this educational activity, has no relevant financial relationships with ineligible companies* to disclose.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.25 AMA PRA Category 1 Credit™
- 2.25 General certificate of attendance
- 2.00 Nurse Practitioners
- 2.00 Florida Board of Nursing
This site is supported on the most recent stable releases of the following browsers:
This site is supported on the following mobile devices:
- Apple iOS mobile devices running iOS 10 or later
- Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.